Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02571036 · ClinicalTrials.gov registry record · Phase 1
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
A Phase 1 study, sponsored by Deciphera Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 282
- Enrollment target
NCT02571036: Completed Phase 1 study, sponsored by Deciphera Pharmaceuticals.
NCT02571036 is a Phase 1 study that has completed, run by Deciphera Pharmaceuticals. The registered enrollment target is 282 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (370% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02571036, a Phase 1 study, has completed, sponsored by Deciphera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 282 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of DCC-2618, administered orally (PO), in adult patients with advanced malignancies. The study consists of 2 parts, a dose-escalation phase, and an expansion phase. All active patients (from both dose-escalation and expansion phases) will then transition into an extension phase.
Primary Outcome
Dose limiting toxicities, AEs, SAEs, discontinuation of drug due to toxicity, physical exams and ECOG PS, ophthalmologic examinations, changes from baseline in laboratory parameters, electrocardiograms, LVEF, and vital signs.
Interventions
- DRUG DCC-2618
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 282 participants |
| Start Date | 2015-11 |
| Est. Completion | 2022-04-29 |
| Phase | Phase 1 |
What the finished NCT02571036 record still lists
NCT02571036 is an interventional study that assigns participants to a tested intervention. The registered 282 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (370% higher).
The record links to 0 conditions, and to 1 intervention - of which DCC-2618 is the first listed.
NCT02571036 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02571036 about?
NCT02571036 is a clinical study titled "A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies". This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of DCC-2618, administered orally (PO), in adult patients with advanced malignancies. The study con...
What is the current status of trial NCT02571036?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 282 participants. The study started on 2015-11. Estimated completion is 2022-04-29.
What interventions are being tested in trial NCT02571036?
The interventions under investigation include: DCC-2618 (DRUG).
Who is sponsoring clinical trial NCT02571036?
This trial is sponsored by Deciphera Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02571036's enrollment target sits among peer trials
282 139th of 2000 higher than 1,861 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02860364 · 282 participants · NA
Comparing Hypothermic Temperatures During Hemiarch Surgery
- NCT04867395 · 282 participants · NA
A Multi-Phase Study Examining Hospital to Home Transitions for Children With Medical Complexity
- NCT05101070 · 282 participants · Phase 1
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
- NCT06276491 · 282 participants · Phase 1
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia